Shots: Sierra will pay $3M upfront and ~$195M milestone payments to Gilead and additional royalties from mid-teen-to-high-twenties on net sales Sierra will continue all currently ongoing clinical studies with Momelotinib following a transition period Momelotinib (a JAK 1/2 and ACVR1 Inhibitor) is in Phase III, has being administered to ~1200 patients, since 2009, and is […]Read More
Tags : from Gilead
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US